by a greater number of randomized trials than are currently available in EGPA. All of the recommendations made for these 3 diseases are conditional, which indicates that there are settings in which the evidence is not strong or an alternative is a reasonable consideration. These recommendations should not be used by any agency to restrict access to therapy or require that certain therapies be utilized prior to other therapies. The physicians on the Voting Panel were primarily rheumatologists, because the recommendations were being developed for rheumatologists in the US. Since AAVs are multisystem diseases, patients with AAVs often receive care from other medical subspecialists (e.g., nephrologists, pulmonologists, and/or otolaryngologists). While the recommendations presented in this guideline are driven by the published data, other medical subspecialists may favor a different management strategy. We encourage rheumatologists to discuss treatment plans and coordinate care with other